Genisphere 特約代理

世界*實驗材料供應商Genisphere  正式授權上海起發為(wei) 其中國代理，Genisphere  在一直是行業(ye) 的*,一直為(wei) 廣大科研客戶提供zui為(wei) 優(you) 質的產(chan) 品和服務,上海起發一直秉承為(wei) 中國科研客戶帶來的產(chan) 品，的服務，簽約Genisphere  就是為(wei) 了給廣大科研客戶帶來更加完善的產(chan) 品和服務,您的滿意將是我們(men) zui大的收獲

Genisphere  中國代理,Genisphere  上海代理，Genisphere  北京代理，Genisphere  廣東(dong) 代理，Genisphere  江蘇代理Genisphere  湖北代理,Genisphere  天津,Genisphere  黑龍江代理,Genisphere  內(nei) 蒙古代理,Genisphere  吉林代理,Genisphere  福建代理,Genisphere  江蘇代理,Genisphere  浙江代理,Genisphere  四川代理,

Genisphere公司專(zhuan) 注於(yu) 核酸標記技術的發明和新產(chan) 品的開發。該公司推出的3 Dendrimer技術是對核酸標記技術的重大創新，具有廣闊的發展前景。3 Dendrimer技術:3 Dendrimer是由多個(ge) 交錯的自然或合成的3單體(ti) 結構單位組成的複雜的分枝狀分子構型。每個(ge) 3單體(ti) 由兩(liang) 條中央部分互補的鏈組成，退火時兩(liang) 條鏈會(hui) 形成一個(ge) 中間雙鏈兩(liang) 頭單鏈的結構。3單體(ti) 之間的單鏈通過堿基互補組成了3 Dendrimer構型。3 Dendrimer的單鏈是標記物的結合位點。特點：靈活的標記：3 Dendrimer可以結合多種標記物，可以滿足多種檢測的需要
信號增強作用：每個(ge) 3 Dendrimer分子平均可以結合200分子的標記物，因此雜交時信號增強了200倍以上

In 1986, the first patent applications covering the design and use of 3 technologywere filed. Determined to build a strong portfolio and reward our scientists, we have worked hard to grow the list of patents. Genisphere was incorporated in 1997 and proudly launched its first 3 Expression Array Detection kit, developed in conjunction with Harvard-affiliated researchers, in 1999.

In 2006, Genisphere was honored to receive a Frost & Sullivan Technology Innovation Award for this product line. With an established business in microarrays, Genisphere turned to RNA amplification technology, offering a new method with a twist—the ability to amplify mRNA in the sense orientation. Product launches included SenseAMP in 2004, RampUP in 2006, and Sensation in 2011. All had a particular focus on clinical FFPE samples. In 2008, Genisphere’s RNA amplification technology was incorporated into the Pathwork Diagnostics Tissue of Origin Test, which was cleared by the FDA in 2010. The Sensation technology was licensed to Affymetrix in 2011 for microarray applications. Genisphere launched the world’s first microRNA labeling kit in 2005. The release of FlashTag in 2007 enabled customers to scale up their microRNA research, offering a single-tube labeling reaction with no purification required. Genisphere’s microRNA labeling technology has been incorporated into microarray products from Invitrogen (2006, 2008) and Luminex products from Marligen (2008). Additional co-marketing (2009) and OEM (2011) structures with Affymetrix validate the power of FlashTag. Single-tube UltraAmp reagents were first launched in 2005, with new varieties added in 2008. Now almost all UltraAmp signal amplifiers are custom made, once again proving the importance of collaboration. Genisphere found particular success in providing custom reagents to improve the limit of detection in lateral flow point-of-care diagnostic tests and licensed 3 technology to BBI Solutions for lateral flow assay development for enhanced performance and sensitivity (2014).

In 2009, Genisphere LLC was formed, inheriting all of the legacy technology and inlectual property from its predecessor, Genisphere, Inc. With established success of the 3 technology in life science and diagnostic applications, the company turned its focus to targeted drug delivery. Since research has shown to be a non-toxic, biocompatible material in vivo, Genisphere aimed to become a commercial source of highly targeted -based nanocarriers. Genisphere's first task was to re-engineer its strands based on three goals for the final 3 construct.

1. Redesigning the sequences with the immune system in mind
2. Incorporating more crosslinking sites for better stability of the core 3 structure
3. Scaling up the manufacturing process to achieve routine production of therapeutic quantities of 3

After meeting these objectives, Genisphere expanded its efforts in cellular targeting. Leveraging its experience in antibody- conjugation, the company studied attachment of 3 to antibody fragments, peptides, sugars, vitamins and other targeting devices for specific cellular delivery. After producing these data, Genisphere established several key collaborations to generate preclinical data showing the versatility and efficacy of the 3 platform in targeted delivery of small drugs, biologics and nucleic acids. To date, the 3 platform has proven to provide cell-specific (cytosolic and nuclear) delivery of drugs with functional intracellular effects without apparent toxicity. The flexibility of the 3 platform to deliver hundreds of tracking labels to targeted tissues provides an option to incorporate a companion diagnostic into the drug development process. Genisphere continues to seek partnerships with biotechnology and pharmaceutical companies. The company is also advancing its own lead oncology compounds based on the 3 drug delivery platform.

公司：www.genisphere.com/

我們(men) 公司zui大優(you) 勢是強大的采購，

1：基本什麽(me) 都能進口，血清，抗體(ti) ，耗材，還有部分限製進口的，

2：貨品全，現經營過700多個(ge) 品牌，基本所有生物試劑耗材都可以進口，特別是冷偏的產(chan) 品那就更有優(you) 勢，

3：提供加急服務，一般1-2周到貨，超過時限加急費全免

4：價(jia) 格公道，絕大部分價(jia) 格有優(you) 勢，當然不能保證100%產(chan) 品都是,因為(wei) 意味著沒有服務.

5：良好的信譽，大部分客戶我們(men) 提供貨到付款服務，客戶包括清華，北大 交大 複旦，中山等100多所大學，ROCHE，阿斯利康，國藥 ，fisher等500多家公司

6：我們(men) 還是Santa,Advanced Biotechnologies Inc,Genisphere ,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. FormuMax Scientific,Inc, GePromegaridege, Glycotope Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,Genisphere , Polysciences,prospecbi, QA-BIO,quickzyme,FULLERLABS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等幾十家國外公司授權代理。
7：我們(men) 還是invitrogen,qiagen,Genisphere am,sigma;Promega,roche,merck, rnd,BD, GE,pierce,BioLegend等*批發，歡迎合作。

菲律宾新利官网开户
：楊建輝
400：
辦公：
*8006

企業(ye) :
:https://www.qfbio.com/
地址：上海市浦東(dong) 新區晨陽路225弄東(dong) 方現代商業(ye) 廣場46號303室(近東(dong) 亭路)